Oncology signposting in a hospital
Oncology signposting in a hospital

Global Oncology Monitors

Capturing real-world anti-cancer drug treatment since 1991

In a highly dynamic therapy area like oncology, you need access to a real-world data source you can trust…

Ipsos’ Global Oncology Monitor, which provides gold-standard data with bespoke analyses and tailored recommendations, is used by today’s leading oncology manufacturers to guide their key business decisions. Why…?

About the Ipsos Global Oncology Monitor

  • 30+ years of real-world anti-cancer prescribing data
  • All solid tumours & haematological malignancies covered
  • Runs in 30+ markets, with globally comparable metrics & regional nuances
  • Led & serviced by dedicated oncology specialists in all regions
  • All analyses & deliverables fully customised to individual client need.
  • The cost efficiency, robustness and impartiality of multi-client research

Oncology Molecular Diagnostics (MDx) Monitor & Other Solutions

Ipsos offers multiple additional studies that address specific oncology business needs, many of which leverage the Global Oncology Monitor framework. These include:  

  • Oncology MDx Monitor
    Tracks the ongoing evolution of the MDx market and its impact on cancer therapy  
  • Oncology Rapid Fire Monitors
    Fast-turnaround deep-dives into specific patient populations  
  • Oncology Conference Assessment Monitors
    Assesses company & competitor performance at key industry conferences
  • Oncology Salesforce Effectiveness Monitors
    Message recall tracking with Ipsos’ RepInsight™
  • CAR-T Monitor
    Multi-stakeholder perspectives on current & future market dynamics
  • Oncology Dashboards
    Interactive tools covering key oncology metrics such as drug uptake, patient & physician profiling, market sizing, source of business, patient journey, market maps, and more.
     

Recent thought leadership
PoV: Oncology: The Disease, Dynamics & Challenges of Market Research - January 2026 update
Online Abstract (ASH 2025): Contrasting real-world treatment landscapes of bispecific antibodies and CAR-T cells in multiple myeloma and diffuse large B-cell lymphoma
PoV: Would You Want to Know? The Paradox of Early Cancer Detection
PoV: Does Everything Really Cause Cancer?
Paper & Podcast: Mastering Complexity: The Path to a Cancer-free Reality
ASCO 2025 Online Abstract: Academic vs Community Practices in Treating Prostate Cancer 

Tell us your oncology business question today.

Related contents